The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults.
about
Fluticasone versus 'extrafine' HFA-beclomethasone dipropionate for chronic asthma in adults and childrenFluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and childrenImpact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.The nanoscale in pulmonary delivery. Part 2: formulation platforms.The sustainability of a community pharmacy intervention to improve the quality use of asthma medication.Uptake and effectiveness of a community pharmacy intervention programme to improve asthma management.Review of the management of childhood asthma in Tasmania.Pharmacological consequences of inhaled drug delivery to small airways in the treatment of asthma.Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.Targeting small airways in asthma: improvement in clinical benefit?Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives
P2860
Q24243904-2ABA07BC-D30F-4D36-B013-149185B0CDFCQ24245474-3B4E6857-9327-4B3A-A4A8-27D39B9B7B9EQ26826860-76B088B5-D5EF-437E-87D1-97C3F8C600B5Q35070070-25F998B4-276A-4249-964C-0A486D4E2933Q36985898-685591CF-98F0-4576-AE80-FD4B450876D6Q37848882-3BF13712-B73D-4110-8A7A-D476774BC39CQ38084336-0F31668F-7C05-49A9-BE21-C9CBC3B65E28Q38112798-D1074115-145B-45AD-92A1-B370005174A3Q38239365-E637176C-71A2-4A1F-8A1D-08972163B39CQ50915470-82578455-3EE2-4213-AF2A-99252D92455EQ53059056-3323DB13-283D-4D64-86A4-036041B1F684Q58877120-373ECB57-27B9-42A7-A5A5-70B5D54071C0
P2860
The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The efficacy and safety of QVA ...... clinical experience in adults.
@ast
The efficacy and safety of QVA ...... clinical experience in adults.
@en
type
label
The efficacy and safety of QVA ...... clinical experience in adults.
@ast
The efficacy and safety of QVA ...... clinical experience in adults.
@en
prefLabel
The efficacy and safety of QVA ...... clinical experience in adults.
@ast
The efficacy and safety of QVA ...... clinical experience in adults.
@en
P1476
The efficacy and safety of QVA ...... clinical experience in adults.
@en
P2093
C P Van Schayck
P2860
P304
P356
10.1111/J.1368-5031.2004.00273.X
P577
2004-07-01T00:00:00Z